Acrivon Therapeutics (ACRV) catalysts

Upcoming FDA decisions and readouts we track for Acrivon Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Acrivon Therapeutics (ACRV, listed on Nasdaq). It concerns ACR-368 (Serous endometrial cancer).

First on the list: the Phase 2B readout for ACR-368 (Serous endometrial cancer), guided by the company to H2 2026.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: ACRV
Next catalyst: H2 2026
Type: Phase 2B readout
Listed options: No

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Acrivon Therapeutics ACRV · Nasdaq	ACR-368	Serous endometrial cancer	H2 2026 company guidance	Phase 2B readout	Verified	8-K exhibit 99.1 ↗	No
Notes — Filing guides "a prespecified simultaneous interim analysis and data update from both all-comer ... serous EC arms of the ACR-368 Phase 2b study in second half of 2026." Source: 8-K exhibit 99.1, filed 12 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Faeth Therapeutics (FTH)Endometrial cancer; HR-positive breast cancer
Whitehawk Therapeutics (WHWK)EGFR wild-type NSCLC, platinum-resistant ovarian and endometrial cancer; Advanced ovarian and endometrial cancers
Verastem Oncology (VSTM)KRAS G12D-mutant solid tumours; Recurrent low-grade serous ovarian cancer